CXCL9 associated with sustained virological response in chronic hepatitis B patients receiving peginterferon alfa-2a therapy: a pilot study

There is lack of a practical biomarker to predict sustained virological response (SVR) in chronic hepatitis B (CHB) patients undergoing peginterferon alfa-2a (PEG-IFN). The aim of this pilot study was to identify immunological features associated with SVR. Consecutive 74 CHB patients receiving 24 we...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	PloS one 2013-10, Vol.8 (10), p.e76798-e76798
Hauptverfasser:	Lee, I-Cheng, Huang, Yi-Hsiang, Su, Chien-Wei, Wang, Yuan-Jen, Huo, Teh-Ia, Lee, Kuei-Chuan, Lin, Han-Chieh
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Alanine Transaminase - blood Alanine Transaminase - metabolism Antigens Antiviral Agents - therapeutic use Bioindicators Biological response modifiers Biomarkers Bone morphogenetic proteins Care and treatment Chemokine CXCL9 - blood Chemokine CXCL9 - metabolism Chemokines Clinical medicine Cytokines Cytokines - blood Cytokines - metabolism Deoxyribonucleic acid DNA Female Gastroenterology Genotype Hepatitis Hepatitis B Hepatitis B e antigen Hepatitis B e Antigens - immunology Hepatitis B surface antigen Hepatitis B virus - genetics Hepatitis B virus - immunology Hepatitis B, Chronic - drug therapy Hepatitis B, Chronic - metabolism Hepatitis B, Chronic - virology Hepatology Hospitals Humans Immunology Infections Interferon Interferon-alpha - therapeutic use IP-10 protein Liver diseases Male Medicine Middle Aged Multivariate analysis Patients Pilot Projects Polyethylene Glycols - therapeutic use Prognosis Proteins Recombinant Proteins - therapeutic use Seroconversion Time Factors Transforming growth factor-b Transforming growth factors Treatment Outcome Viral antigens Viral Load γ-Interferon
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	There is lack of a practical biomarker to predict sustained virological response (SVR) in chronic hepatitis B (CHB) patients undergoing peginterferon alfa-2a (PEG-IFN). The aim of this pilot study was to identify immunological features associated with SVR. Consecutive 74 CHB patients receiving 24 weeks (for hepatitis B e antigen (HBeAg)-positive) or 48 weeks (for HBeAg-negative) PEG-IFN, were prospectively enrolled. Serum HBV viral loads, hepatitis B surface antigen (HBsAg), CXCL9, IFN-γ-inducible protein 10 (IP-10), interferon-gamma (IFN-γ) and transforming growth factor beta (TGF-β) were measured at baseline and week 12. SVR was defined as HBeAg seroconversion combined with viral load
ISSN:	1932-6203 1932-6203
DOI:	10.1371/journal.pone.0076798